Barclays Sticks to Its Sell Rating for Novartis AG (NOVN)
Raymond James, Cantor Bullish on UniQure Following FDA Update
Novartis Says Longer-Term Data Highlight Kisqali's Efficacy as Early Breast Cancer Treatment
Deutsche Bank Sticks to Their Hold Rating for Novartis AG (NOVN)
Novartis Announces Positive Results From Late-Stage Study on Fabhalta
On Saturday, Novartis Announced Longer-term Results From Phase 3 ASC4FIRST Trial Of Scemblix (Asciminib) Compared To Standard-Of-Care Tyrosine Kinase Inhibitors And Imatinib Alone In Adult Patients With Newly Diagnosed Chronic Myeloid Leukemia
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
103827296 : Halo Medan hai hai English understand I'm sorry
72627089 : fractional shares
72627089 : would like to chat about fractional shares
(R-long)103834298 : stop all
l0lBElBgG : k